Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myosin-Ie (MYO1E) is a nonmuscle class I myosin protein that acts as an ATP-dependent actin-based molecular motor, critical for intracellular movement, membrane trafficking, and the organization of the cytoskeleton[1][3][5][6]. It is characterized by a long “tail” with SH3 and Pleckstrin Homology (PH) domains, which allow it to bind lipids and interact with multiple proteins[1][2][3][5]. MYO1E is essential for the structure and function of kidney podocyte cells, where it maintains the glomerular filtration barrier; mutations in MYO1E cause inherited forms of nephrotic syndrome and focal segmental glomerulosclerosis[1][3][7]. In mammalian cells, MYO1E is involved in clathrin-mediated endocytosis, trafficking of clathrin-coated vesicles, and rapid rearrangement of actin filaments[2][3]. Overexpression or mutation of MYO1E is implicated in cancer progression (notably lung adenocarcinoma and basal-like breast cancer) and kidney diseases, linking MYO1E to both cytoskeletal integrity and disease pathogenesis[1][3][7][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myosin-Ie (MYO1E).